Synthekine

📍 Menlo Park, United States🗓 Founded 2018👥 95 employees💰 Last funded Mar 2019
Biotechnology Research🌐 synthekine.com
Website LinkedIn
Synthekine is an engineered cytokine therapeutics company developing disease-optimized treatments. The company uses immunological insights to guide targeted protein engineering to generate transformative medicines for cancer and autoimmune disorders. Using the principles of cytokine partial agonism and immunological specificity, Synthekine designs differentiated therapeutics to be both safe and efficacious. Its lead programs have shown promising efficacy and tolerability in preclinical studies, and it is developing additional cytokine partial agonists that selectively modulate key pathways of the immune system.
1
Total investors
1
Early stage
0
Mid stage
0
Late stage
2018
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
1
Frequently asked questions
Who invested in Synthekine?
Synthekine has 1 investors on record on gritt.io, including 1 early-stage backers.
When did Synthekine last raise funding?
The most recent investment in Synthekine recorded on gritt.io was in March 2019.
When was Synthekine founded?
Synthekine was founded in 2018.
What industry is Synthekine in?
Synthekine operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Synthekine based?
Synthekine is headquartered in Menlo Park, United States.